Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study

Neurological Sciences

Volumn 31, Issue SUPPL. 3, 2010, Pages

  Sangalli, F ^a   Moiola, L ^a   Bucello, S ^a   Annovazzi, P ^b   Rizzo, A ^b   Radaelli, M ^a   Vitello, G ^c   Grimaldi, L M E ^c   Ghezzi, A ^b   Martinelli, V ^a   Comi, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Centro Studi SM   (Italy)

^c Ospedale Giglio HSR   (Italy)

Author keywords

Efficacy; Multiple sclerosis; Natalizumab; Safety

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960379564     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-010-0344-z     Document Type: Conference Paper

References (3)

1. Yednock TA, Cannon C, Fritz LC et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 356:63-66
2. Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899-910
3. Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911-923